Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus

No hay miniatura disponible

Fecha

2014-01-01

Director de tesis/Asesor

Título de la revista

ISSN de la revista

Título del volumen

Publicador

Elsevier

Editor

Compartir

Documentos PDF

Resumen

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment. © 2014 Fabio Bonilla-Abadía et al.

Descripción

Palabras clave

Citación

ARK

ARXIV

Barcode

Bibcode

EAN13

DOI

http://dx.doi.org/10.1155/2014/731806

EISSN

GOVDOC

Handle

IGSN

ISBN

ISMN

ISSN

0896-8411

ISTC

ISSN-L

LSID

Local

Other

http://www.scopus.com/inward/record.url?eid=2-s2.0-84893658088&partnerID=tZOtx3y1

OLIB

PISSN

PMID

PURL

SICI

Slug

SoundCloud

UPC

URL

URN

YouTube

WOS